Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.

Bergdorf KN, Ferguson DC, Mehrad M, Ely K, Stricker T, Weiss VL.

Endocr Relat Cancer. 2019 Apr 1. pii: ERC-19-0074.R1. doi: 10.1530/ERC-19-0074. [Epub ahead of print]

PMID:
30965283
2.

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1433. doi: 10.1158/1078-0432.CCR-18-4268. No abstract available.

PMID:
30770492
3.

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.

PMID:
30770490
4.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
5.

Correction: Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.

Stricker T, Arteaga CL.

Cancer Discov. 2019 Feb;9(2):302. doi: 10.1158/2159-8290.CD-18-1514. No abstract available.

PMID:
30737216
6.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1431.

7.

Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis.

Hebron KE, Li EY, Arnold Egloff SA, von Lersner AK, Taylor C, Houkes J, Flaherty DK, Eskaros A, Stricker TP, Zijlstra A.

Sci Rep. 2018 Feb 16;8(1):3208. doi: 10.1038/s41598-018-21467-x.

8.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC.

Leuk Res. 2018 Feb;65:67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2.

9.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

10.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1433.

11.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

12.

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression.

Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R, White KP.

PLoS Genet. 2017 Mar 6;13(3):e1006589. doi: 10.1371/journal.pgen.1006589. eCollection 2017 Mar.

13.

Optimization by infusion of multiple reaction monitoring transitions for sensitive quantification of peptides by liquid chromatography/mass spectrometry.

Alghanem B, Nikitin F, Stricker T, Duchoslav E, Luban J, Strambio-De-Castillia C, Muller M, Lisacek F, Varesio E, Hopfgartner G.

Rapid Commun Mass Spectrom. 2017 May 15;31(9):753-761. doi: 10.1002/rcm.7839.

PMID:
28199054
14.

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.

Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS.

Mol Cancer Res. 2017 Mar;15(3):259-268. doi: 10.1158/1541-7786.MCR-16-0280-T. Epub 2016 Dec 30.

15.

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA.

Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.

16.

Frequency and Pathophysiology of Acute Liver Failure in Ornithine Transcarbamylase Deficiency (OTCD).

Laemmle A, Gallagher RC, Keogh A, Stricker T, Gautschi M, Nuoffer JM, Baumgartner MR, Häberle J.

PLoS One. 2016 Apr 12;11(4):e0153358. doi: 10.1371/journal.pone.0153358. eCollection 2016.

17.
18.

C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.

Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R.

Cancer Biol Ther. 2016;17(1):91-103. doi: 10.1080/15384047.2015.1108495.

19.

Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.

Stricker T, Arteaga CL.

Cancer Discov. 2015 Nov;5(11):1124-6. doi: 10.1158/2159-8290.CD-15-1166. Erratum in: Cancer Discov. 2019 Feb;9(2):302.

20.

Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.

Barham W, Chen L, Tikhomirov O, Onishko H, Gleaves L, Stricker TP, Blackwell TS, Yull FE.

BMC Cancer. 2015 Sep 30;15:647. doi: 10.1186/s12885-015-1652-8.

21.

Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.

Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, Shyr Y, Guo Y.

Brief Bioinform. 2016 Mar;17(2):224-32. doi: 10.1093/bib/bbv057. Epub 2015 Aug 5.

22.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.

23.

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.

Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY.

Clin Cancer Res. 2015 Feb 15;21(4):870-81. doi: 10.1158/1078-0432.CCR-14-2481. Epub 2014 Dec 9.

24.

Surgical resection margins in desmoid-type fibromatosis: a critical reassessment.

Cates JM, Stricker TP.

Am J Surg Pathol. 2014 Dec;38(12):1707-14. doi: 10.1097/PAS.0000000000000276.

PMID:
25392923
25.

Detection of internal exon deletion with exon Del.

Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y.

BMC Bioinformatics. 2014 Oct 16;15:332. doi: 10.1186/1471-2105-15-332.

26.

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.

Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY.

Oral Oncol. 2015 Jan;51(1):53-8. doi: 10.1016/j.oraloncology.2014.08.014. Epub 2014 Sep 23.

PMID:
25255959
27.

Desmoid-type fibromatosis-associated Gardner fibromas: prevalence and impact on local recurrence.

Cates JM, Stricker TP, Sturgeon D, Coffin CM.

Cancer Lett. 2014 Oct 28;353(2):176-81. doi: 10.1016/j.canlet.2014.07.020. Epub 2014 Jul 23.

PMID:
25064609
28.

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS.

Clin Cancer Res. 2015 Feb 1;21(3):632-41. doi: 10.1158/1078-0432.CCR-13-3310. Epub 2014 Jul 23.

29.

SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP.

Cancer Cell. 2014 Apr 14;25(4):455-68. doi: 10.1016/j.ccr.2014.02.007. Epub 2014 Mar 20.

30.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

31.

SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.

Papp G, Krausz T, Stricker TP, Szendrői M, Sápi Z.

Genes Chromosomes Cancer. 2014 Feb;53(2):168-76. doi: 10.1002/gcc.22128. Epub 2013 Nov 5.

PMID:
24327545
32.

Systematic mapping of occluded genes by cell fusion reveals prevalence and stability of cis-mediated silencing in somatic cells.

Looney TJ, Zhang L, Chen CH, Lee JH, Chari S, Mao FF, Pelizzola M, Zhang L, Lister R, Baker SW, Fernandes CJ, Gaetz J, Foshay KM, Clift KL, Zhang Z, Li WQ, Vallender EJ, Wagner U, Qin JY, Michelini KJ, Bugarija B, Park D, Aryee E, Stricker T, Zhou J, White KP, Ren B, Schroth GP, Ecker JR, Xiang AP, Lahn BT.

Genome Res. 2014 Feb;24(2):267-80. doi: 10.1101/gr.143891.112. Epub 2013 Dec 5.

33.

The genomic map of breast cancer: which roads lead to better targeted therapies?

Balko JM, Stricker TP, Arteaga CL.

Breast Cancer Res. 2013;15(4):209. Review.

34.

Cross-sectional observational study of 208 patients with non-classical urea cycle disorders.

Rüegger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, Gautschi M, Glahn EM, Grünert SC, Hennermann J, Hochuli M, Huemer M, Karall D, Kölker S, Lachmann RH, Lotz-Havla A, Möslinger D, Nuoffer JM, Plecko B, Rutsch F, Santer R, Spiekerkoetter U, Staufner C, Stricker T, Wijburg FA, Williams M, Burgard P, Häberle J.

J Inherit Metab Dis. 2014 Jan;37(1):21-30. doi: 10.1007/s10545-013-9624-0. Epub 2013 Jun 19.

35.
36.

The different morphologies of urachal adenocarcinoma do not discriminate genomically by micro-RNA expression profiling.

Bissonnette ML, Kocherginsky M, Tretiakova M, Jimenez RE, Barkan GA, Mehta V, Sirintrapun SJ, Steinberg GD, White KP, Stricker T, Paner GP.

Hum Pathol. 2013 Aug;44(8):1605-11. doi: 10.1016/j.humpath.2013.01.008. Epub 2013 Mar 22.

PMID:
23528864
37.

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY.

Oral Oncol. 2013 Jun;49(6):525-33. doi: 10.1016/j.oraloncology.2013.02.003. Epub 2013 Mar 13.

PMID:
23490885
38.
39.

CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, Yu S, Ko J, Sandall BP, Stricker T, Anastasi J, Grossman RL, Cunningham JM, Le Beau MM, White KP.

Blood. 2013 Feb 7;121(6):975-83. doi: 10.1182/blood-2012-04-426965. Epub 2012 Dec 3.

40.

SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.

Papp G, Changchien YC, Péterfia B, Pecsenka L, Krausz T, Stricker TP, Khoor A, Donner L, Sápi Z.

Mod Pathol. 2013 Mar;26(3):393-403. doi: 10.1038/modpathol.2012.190. Epub 2012 Nov 23.

41.

Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance.

Köhli-Wiesner A, Stahlberger L, Bieli C, Stricker T, Lauener R.

J Allergy (Cairo). 2012;2012:790910. doi: 10.1155/2012/790910. Epub 2011 Jul 19.

42.

Nevus versus melanoma: to FISH, or not to FISH.

Song J, Mooi WJ, Petronic-Rosic V, Shea CR, Stricker T, Krausz T.

Adv Anat Pathol. 2011 May;18(3):229-34. doi: 10.1097/PAP.0b013e3182169b69. Review.

PMID:
21490440
43.

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic.

Stricker T, Catenacci DV, Seiwert TY.

Semin Oncol. 2011 Apr;38(2):173-85. doi: 10.1053/j.seminoncol.2011.01.013. Review.

PMID:
21421108
44.

Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium.

Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, Baumgartner M, Cederbaum S, Diaz GA, Feigenbaum A, Gallagher RC, Harding CO, Kerr DS, Lanpher B, Lee B, Lichter-Konecki U, McCandless SE, Merritt JL, Oster-Granite ML, Seashore MR, Stricker T, Summar M, Waisbren S, Yudkoff M, Batshaw ML.

Mol Genet Metab. 2010;100 Suppl 1:S97-105. doi: 10.1016/j.ymgme.2010.01.014. Epub 2010 Feb 10. Review.

45.

Negative regulation of activated alpha-2 integrins during thrombopoiesis.

Zou Z, Schmaier AA, Cheng L, Mericko P, Dickeson SK, Stricker TP, Santoro SA, Kahn ML.

Blood. 2009 Jun 18;113(25):6428-39. doi: 10.1182/blood-2008-08-175356. Epub 2009 Mar 3.

46.

Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.

Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP.

Science. 2009 Feb 27;323(5918):1218-22. doi: 10.1126/science.1157669. Epub 2009 Jan 22.

47.

Endoscopic and EUS features of groove pancreatitis masquerading as a pancreatic neoplasm.

de Tejada AH, Chennat J, Miller F, Stricker T, Matthews J, Waxman I.

Gastrointest Endosc. 2008 Oct;68(4):796-8. doi: 10.1016/j.gie.2008.02.015. Epub 2008 Jun 4. No abstract available.

PMID:
18534585
48.

Visual diagnosis: an 8-month-old infant who has an erupting rash.

Stricker T, Lips U, Sennhauser FH.

Pediatr Rev. 2007 Jun;28(6):231-4. No abstract available.

PMID:
17545335
49.

Allergic contact dermatitis due to transdermal contraception patch.

Stricker T, Sennhauser FH.

J Pediatr. 2006 Jun;148(6):845. No abstract available.

PMID:
16769403

Supplemental Content

Loading ...
Support Center